Agile Therapeutics Inc (AGRX) Stock: Aisling Capital Unloads 300,000 Shares

Published on October 4, 2016 at 4:55 am by Insider Monkey Staff in Hedge Funds,News

Page 1 of 9

In a new 13D filing, Dennis Purcell‘s Aisling Capital reported lowering its stake in Agile Therapeutics Inc (NASDAQ:AGRX) to 2.28 million shares, which account for 7.9% of the company’s outstanding stock. The fund’s stake was reduced from 2.58 million shares held as of the end of June.

Agile Therapeutics Inc (NASDAQ:AGRX) is a pharmaceutical company that produces women’s health products, such as contraceptives. Over the past 12 months, the company’s stock has gained 1.39%. For the second quarter of 2016, Agile Therapeutics reported a loss per share of $0.29, and a net loss of $8.42 million, compared to a loss per share of $0.38 and a net loss of $8.49 million for the same quarter of the previous year.

Image Point Fr/Shutterstock.com

Eight investors in our database were bullish on Agile Therapeutics Inc (NASDAQ:AGRX) at the end of June, same as a quarter earlier. Some of the smart managers that reported long positions in the company as of June 30 included Phill Gross and Robert Atchinson’s Adage Capital Management, which held a position worth $12.94 million, Joseph Edelman’s Perceptive Advisors, with a position valued at $3.91 million, Chuck Royce’s Royce & Associates, James E. Flynn’s Deerfield Management, and Peter Kolchinsky’s RA Capital Management.

Follow Agile Therapeutics Inc (NASDAQ:AGRX)Follow Agile Therapeutics Inc (NASDAQ:AGRX)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Aisling Capital III	2,275,455	0	2,275,455	0	2,275,455	7.9%
Aisling Capital Partners III	2,275,455	0	2,275,455	0	2,275,455	7.9%
Aisling Capital Partners III	2,275,455	0	2,275,455	0	2,275,455	7.9%
Steven Elms	961	2,275,455	961	2,275,455	2,276,416	7.9%
Dennis Purcell	1,879	2,275,455	1,879	2,275,455	2,277,334	7.9%
Andrew Schiff	460	2,275,455	460	2,275,455	2,275,915	7.9%

Dennis Purcell

Aisling Capital

Page 1 of 9 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

(Amendment No. 3)*

Agile Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

00847L100

(CUSIP Number)

Lloyd Appel

Aisling Capital

888 Seventh Avenue, 12th Floor

New York, NY 10106

(212) 651-6380

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

September 30, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).